BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
Keyword: Ustekinumab
1
Clinical outcomes and drug sustainability after non-medical switch from ustekinumab originator to biosimilars in inflammatory bowel disease
12/27/2025 2:50:53 AM | Browse: 121 | Download: 361
2
Risankizumab is effective following ustekinumab failure in Crohn’s disease: A real-world study from a tertiary center
12/5/2025 11:28:01 AM | Browse: 72 | Download: 235
3
Refractory ulcerative colitis: Upadacitinib versus other biologics
9/11/2024 6:37:28 AM | Browse: 182 | Download: 551
4
Exit strategies in inflammatory bowel disease: Looking beyond anti-tumor necrosis factors
4/25/2023 11:32:55 PM | Browse: 281 | Download: 858
5
Approach to medical therapy in perianal Crohn’s disease
7/6/2021 2:31:17 AM | Browse: 766 | Download: 1341
6
Recalcitrant paradoxical pustular psoriasis induced by infliximab: Two case reports
5/11/2021 11:07:20 AM | Browse: 642 | Download: 1699
7
First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus
11/20/2020 4:04:17 AM | Browse: 1100 | Download: 2648
8
Ustekinumab: ‘Real-world’ outcomes and potential predictors of nonresponse in treatment-refractory Crohn’s disease
8/21/2019 9:19:18 AM | Browse: 1016 | Download: 2072
9
Interleukin 12/interleukin 23 pathway: Biological basis and therapeutic effect in patients with Crohn's disease
9/25/2018 3:44:36 AM | Browse: 1053 | Download: 1630
10
Role of leptin in the progression of psoriatic, rheumatoid and osteoarthritis
3/11/2016 10:58:00 AM | Browse: 1418 | Download: 2489
11
Psoriasis: Biologic treatment and liver disease
11/13/2014 4:59:00 PM | Browse: 1769 | Download: 1833
12
When combination therapy isn’t working: Emerging therapies for the management of inflammatory bowel disease
9/3/2014 2:27:00 PM | Browse: 1158 | Download: 1602
Write to the Help Desk
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.